Preprint
Article

This version is not peer-reviewed.

Medication Adherence and Quality of Life Among Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors in Saudi Arabia: A Cross-Sectional Study

Submitted:

08 November 2026

Posted:

09 November 2026

You are already at the latest version

Abstract
Tyrosine kinase inhibitors (TKIs) have transformed the treatment of chronic myeloid leukemia (CML) patients, enabling long-term disease control while highlighting quality of life (QoL) and medication adherence. In Saudi Arabia, data on the relationship of TKI adherence and QoL remains limited. This study evaluated QoL, medication adherence, and their associated factors. A cross-sectional study of adult CML patients on TKI therapy at two Saudi tertiary centers assessed QoL using the EORTC QLQ-CML24 and QLQ-C30, and adherence using the MARS-5. Linear regression analyzed factors associated with global health status, while logistic regression examined factors associated with adherence. Among 100 patients (mean age 46.99 ± 14.26 years) 48% were female and 61% were adherent. Adherent patients had better emotional functioning, with significant lower fatigue, nausea and vomiting, pain, dyspnea, insomnia, and financial difficulties (all p < 0.05). Female sex was independently associated with higher odds of adherence (aOR 3.15, 95% CI 1.05–9.45, p = 0.041). Adherence was associated with a higher global health status score, but not significantly (adjusted β = 4.40, 95% CI -3.81–12.61, p = 0.289). These findings support integrating adherence assessment with patient-reported outcomes and warrant prospective studies to establish this relationship.
Keywords: 
;  ;  ;  ;  ;  
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.